Elevated p21 expression is associated with poor prognosis of rectal stromal tumors after resection

Journal of Surgical Oncology

Volumn 98, Issue 2, 2008, Pages 117-123

  Hu, Tsung Hui ^a   Tai, Ming Hong ^b   Chuah, Seng Kee ^a   Chen, Hong Hwa ^a   Lin, Jui Wei ^a   Huang, Hsuan Ying ^a   Chou, Yeh Pin ^a   Yi, Li Na ^a   Kuo, Chung Mou ^a   Changchien, Chi Sin ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gists; P21; P53; PCNA; Prognosis; Rectum

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER SURVIVAL; CELL TYPE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MALE; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RECTUM RESECTION; RECTUM STROMA TUMOR; RECTUM TUMOR; STATISTICAL SIGNIFICANCE; STROMA; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-KIT; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49149109883     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21094     Document Type: Article

References (39)

1. Rudolph P, Gloeckner K, Parwaresch R, et al.: Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic study. Hum Pathol 1998;29:791-800.
2. Changchien CR, Wu MC, Tasi WS, et al.: Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 2004;47:1922-1929.
3. Hassan I, You YN, Dozois EJ, et al.: Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: Implications for surgical management and adjuvant therapies. Dis Colon Rectum 2006;49:609-615.
4. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
5. Antonescu CR, Sommer G, Sarran L, et al.: Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337.
6. Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
7. Hu TH, Lin JW, Changchien CS, et al.: Immunohistochemical analyses of gastric stromal tumors in Taiwanese. J Formos Med Assoc 2003;102:707-714.
8. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465.
9. Ueyama T, Guo KJ, Hashimoto H, et al.: A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992;69:947-955.
10. Hu TH, Chuah SK, Lin JW, et al.: Expression and prognostic role of molecular markers in 99 KIT-positive gastric stromal tumors in Taiwanese. World J Gastroenterol 2006;12:595-602.
11. Franquemont DW, Frierson HF Jr: Muscle differentiation and clinicopathologic features of gastrointestinal stromal tumors. Am J Surg Pathol 1992;16:947-954.
12. Fletcher CD: Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol 2002;33:455.
13. Carrillo R, Candia A, Rodriguez-Peralto JL, et al.: Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997;28:160-165.
14. Wong NA, Young R, Malcomson RD, et al.: Prognostic indicators for gastrointestinal stromal tumours: A clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003;43:118-126.
15. Franquemont DW: Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-47.
16. Sabah M, Cummins R, Leader M, et al.: Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: Markers with potential prognostic implications. Hum Pathol 2006;37:648-655.
17. Cayrol C, Knibiehler M, Ducommun B: p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998;16:311-320.
18. Macleod KF, Sherry N, Hannon G, et al.: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-944.
19. el-Deiry WS, Tokino T, Velculescu VE, et al.: WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
20. Parker SB, Eichele G, Zhang P, et al.: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-1027.
21. Nemoto Y, Mikami T, Hana K, et al.: Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: Relevance of cellularity and p27kip1. Pathol Int 2006;56:724-731.
22. Emory TS, Sobin LH, Lukes L, et al.: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol 1999;23:82-87.
23. Feakins RM: The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005;46:270-279.
24. Bravo R, Frank R, Blundell PA, et al.: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987;326:515-517.
25. Dulic V, Stein GH, Far DF, et al.: Nuclear accumulation of p21Cip1 at the onset of mitosis: A role at the G2/M-phase transition. Mol Cell Biol 1998;18:546-557.
26. Hui AM, Kanai Y, Sakamoto M, et al.: Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997;25:575-579.
27. Shi YZ, Hui AM, Takayama T, et al.: Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 2000;83:50-55.
28. Migaldi M, Sgambato A, Garagnani L, et al.: Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6:3131-3138.
29. Halaban R, Cheng E, Zhang Y, et al.: Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene 1998;16:2489-2501.
30. Michieli P, Chedid M, Lin D, et al.: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.
31. Pindzola JA, Palazzo JP, Kovatich AJ, et al.: Expression of p21WAF1/CIP1 in soft tissue sarcomas: A comparative immunohistochemical study with p53 and Ki-67. Pathol Res Pract 1998;194:685-691.
32. Liu FY, Qi JP, Xu FL, et al.: Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor. World J Gastroenterol 2006;12:4161-4165.
33. Qin LF, Ng IO, Fan ST, et al.: p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998;79:424-428.
34. Qin LF, Ng IO: Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 2001;172:7-15.
35. Ng IO, Lai EC, Fan ST, et al.: Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 1994;73:2268-2274.
36. Gao X, Chen YQ, Wu N, et al.: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995;11:1395-1398.
37. Toquet C, Le Neel JC, Guillou L, et al: Elevated (> or =10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: A study of 35 cases. Dig Dis Sci 2002;47:2247-2253.
38. Panizo-Santos A, Sola I, Vega F, et al.: Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 2000;8:133-144.
39. Suster S, Fisher C, Moran CA: Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22:863-872.